Financial Performance Highlights

Standalone Performance (FY26):

  • Full year revenue: ₹1,662 crores (up 4% YoY)
  • Gross margin: 68.1% (expanded by 128 bps from previous year's 66.8%)
  • EBITDA: ₹446 crores
  • EBITDA margin: 26.8% (within guided range of 25-27%)

Standalone Performance (Q4 FY26):

  • Quarterly revenue: ₹443 crores (up 5.2% YoY, 6% sequentially)
  • Gross profit: ₹295 crores
  • EBITDA: ₹121 crores
  • EBITDA margin: 27.3%
  • Highest ever standalone quarterly revenue

Consolidated Performance (FY26):

  • Full year revenue: ₹1,875 crores (up 12.3% YoY)
  • Domestic business growth: 20%
  • International business growth: 9%
  • H2 growth: 21% above H1 (₹847 crores to ₹1,029 crores)

Consolidated Performance (Q4 FY26):

  • Quarterly revenue: ₹534 crores (up 21% YoY)
  • Gross profit: ₹356 crores
  • Gross margin: 66.7%
  • Domestic growth: 25%
  • International growth: 19%
  • EBITDA: ₹112 crores (lower than standalone due to consolidation of low-margin acquisitions and ₹9 crores one-time regulatory and cost provisions in international subsidiary)

Strategic Business Updates

Revenue Mix Shift:

  • Infusion Therapy now accounts for 50% of revenue (down from 57% in Q4 FY25)
  • Renal segment: 11% and steadily rising
  • Cardiology, Critical Care and other acquisitions contributing to over 50% of revenue
  • Higher technology segments now contributing majority of revenue

Acquisitions and Integration:

  • PendraCare and Citieffe: Integration fully underway
  • Revenue split: Approximately 50% Europe, 50% rest of world
  • Citieffe has 35-40% business in North America (US and Mexico)
  • Q4 contribution: ₹65 crores total (₹43-44 crores from Citieffe, balance from PendraCare)
  • Medyneo Brazil: Acquisition completed for approximately $40,000 to fast-track entry into Brazilian market (largest medical device market in South America at $13-15 billion)
  • ANVISA and import licenses acquired, saving 18-24 months regulatory timeline

Product Development and Launches:

  • 35 new products launched across group in FY26
  • 20 new products on standalone basis
  • Working on drug-eluting balloons, intravascular lithotripsy, and other high-end products
  • 399 patents at group level

Segment Performance:

  • Renal Platform: 450 dialysis machines placed in FY26, taking installed capacity to approximately 1,000 machines
  • Cardiology: 11,000 stents deployed
  • Clinical Registry: 2,000-patient study with over 650 patients enrolled
  • US Business: Picking up momentum with multiple customer projects active

Balance Sheet and Capital Allocation

  • Consolidated cash: ₹842 crores (strategic reserve for future initiatives)
  • FY26 capex: ₹296 crores (plants in Haridwar, Faridabad, Mitrol, YEIDA Medical Park)
  • Operating cash flows to meet regular capex requirements

Forward-Looking Guidance (FY27)

Revenue Guidance:

  • Consolidated: ₹2,300-2,400 crores (includes full year consolidation of PendraCare and Citieffe)
  • Standalone: ₹1,900-1,950 crores
  • Domestic business: Growing upwards of 20%
  • International business: Growing upwards of 15%

Margin Guidance:

  • Standalone EBITDA margin: 25-27%
  • Consolidated EBITDA margin: 23-25% (subsidiaries operating at lower margins)

Capex Guidance:

  • FY27 capex: ₹200-225 crores (lower than previous year's ₹296 crores)
  • Focus on automation to mitigate wage revision impacts

Market Challenges and Mitigation Strategies

External Headwinds:

  • Gulf war disruption affecting 6-8% of revenue from West Asia
  • Logistics bottlenecks affecting shipping from India
  • 20% aggregate increase in raw material prices (crude-linked)
  • Freight cost increases and minimum wage revision in Haryana

Mitigation Measures:

  • Maintained 2.5-3 months inventory to cushion raw material impact
  • Price increases of 3-5% implemented with customers
  • Rupee depreciation benefits (60-70% export business)
  • Cost-saving projects: alternative supply sources, indigenous sourcing, in-house manufacturing
  • Gamma plant now fully operational providing savings

Gross Margin Outlook:

  • Potential erosion from 68% to approximately 66% (200-300 bps impact)
  • Impact could minimize if crude prices soften from current $100-110 levels

Operational Metrics

  • Inventory days: Increased from 50 to 58 days (standalone increase of ₹30 crores)
  • Receivable days: Increased from 68 to 86 days primarily due to international business support
  • Capacity utilization: 65-70% post QIP-1 expansion

Regional Business Updates

  • Europe: Bounced back with new customer additions and strong pipeline
  • US: Recovery after tariff-related setbacks, new products in FDA approval pipeline
  • Brazil: Building clinical and sales teams for direct market entry
  • India: Benefiting from import substitution trend (60-70% medical device market import-driven)

Category-wise Performance

  • Citieffe: Calendar 2025 revenue €17.5 million (flat due to cancelled Latam tender)
  • PendraCare: Calendar 2025 revenue €8 million
  • FY27 growth expectation: Citieffe 10-12% in euro terms, PendraCare growth restricted due to Middle East exposure

Management Commentary

The company characterized FY26 as a "year of deliberate transition" toward high-technology, high-complexity, high-growth segments. The strategy focuses on becoming a globally recognized brand in high-end medical devices over the next 5 years, with continued investments in orthopedics, cardiology, neonatology, and oncology segments.